Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,DVAX,81155000,114563000,,,4473000,,4473000,19913000,30755000,10842000,10842000,,-3109000,,,,0,52767000,41925000,22012000,-6369000,,4473000,4473000,1372679000,564529000,83380000,159196000,647909000,114000,-1288700000,107031000,2225000,-713000,4067000,129608000,204642000,-713000,57711000,583906000,216196000,105900000,219959000,86451000,12079000,-62687000,127459000,-63752000,29628000,3335000,5899000,947000,50556000,185000,110788000,1769000,-17605000,-21906000,-27240000,10699000,-1065000,379264000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,15.290001,4.27095,3.58 - 20.4,-1.5299988,-0.07499994,3.58,20.4,1620331200,1635937140,1636372800,-0.782,0.2,0.71,-3.0318513,18.58 - 20.4,19.46,19.21,19.22,8,10,finmb_423490,NasdaqCM,Dynavax Technologies Corporation,USD,2951515,10139650,26.577467,0.533,11.395,7.4750004,0.65598947,9.807246,9.062755,0.9240876,2161804032,94.350006,35.403378,15,America/New_York,EDT,-14400000,2,NCM,REGULAR,us_market,Dynavax Technologies Corporatio,18.87,1630506458,-0.58999825,20.14,20.4,18.58,3588353,1.23,,,20.4,3.58,11.4,9.81,2.95M,10.14M,114.56M,,105.83M,0.31%,76.22%,20.28M,8.95,22.32%,17.67%,18.99M,,,,,,0.00%,,,1:10,"Nov 09, 2014","Dec 30, 2020","Jun 29, 2021",-3.37%,7.50%,1.62%,-8.05%,169.07M,1.51,"1,877.80%",6.53M,17.09M,-5.7M,-0.78,,345.8M,3.01,256.34M,307.44,2.85,0.53,105.26M,-1.16M,Value,94608,Healthcare,245,5,6,"Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.",EmeryVille,510 848 5100,CA,8,1609372800,1625097600,3,United States,http://www.dynavax.com,86400,5,2100 Powell Street,510 848 1327,Drug Manufacturers—Specialty & Generic,Suite 900
t-1,DVAX,97565000,114563000,,,891000,,891000,20401000,50952000,30551000,30551000,,-4712000,,,,0,83335000,52784000,32383000,-29660000,,891000,821000,1393947000,390357000,99762000,83939000,490119000,114000,-1293173000,67251000,2197000,-1126000,3894000,79055000,109422000,-1126000,56495000,427533000,153619000,83994000,179889000,68846000,3154000,-20886000,78045000,-22633000,29628000,32303000,-7083000,32303000,46971000,-731000,38032000,1759000,-5157000,-61333000,-27240000,30910000,-1747000,318111000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,15.290001,4.27095,3.58 - 20.4,-1.5299988,-0.07499994,3.58,20.4,1620331200,1635937140,1636372800,-0.782,0.2,0.71,-3.0318513,18.58 - 20.4,19.46,19.21,19.22,8,10,finmb_423490,NasdaqCM,Dynavax Technologies Corporation,USD,2951515,10139650,26.577467,0.533,11.395,7.4750004,0.65598947,9.807246,9.062755,0.9240876,2161804032,94.350006,35.403378,15,America/New_York,EDT,-14400000,2,NCM,REGULAR,us_market,Dynavax Technologies Corporatio,18.87,1630506458,-0.58999825,20.14,20.4,18.58,3588353,1.23,,,20.4,3.58,11.4,9.81,2.95M,10.14M,114.56M,,105.83M,0.31%,76.22%,20.28M,8.95,22.32%,17.67%,18.99M,,,,,,0.00%,,,1:10,"Nov 09, 2014","Dec 30, 2020","Jun 29, 2021",-3.37%,7.50%,1.62%,-8.05%,169.07M,1.51,"1,877.80%",6.53M,17.09M,-5.7M,-0.78,,345.8M,3.01,256.34M,307.44,2.85,0.53,105.26M,-1.16M,Value,94608,Healthcare,245,5,6,"Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.",EmeryVille,510 848 5100,CA,8,1609372800,1625097600,3,United States,http://www.dynavax.com,86400,5,2100 Powell Street,510 848 1327,Drug Manufacturers—Specialty & Generic,Suite 900
t-2,DVAX,56396000,114563000,,,-15467000,,-15467000,15911000,5943000,-9968000,-9968000,,-4805000,,,,0,19550000,29518000,13607000,-5499000,,-15467000,-15467000,1352374000,294579000,58693000,54988000,353272000,110000,-1294064000,2568000,2297000,273000,3810000,32073000,77411000,273000,57150000,290015000,132963000,22661000,179811000,63689000,3312000,11119000,14485000,14342000,29628000,66000,-24783000,66000,-604000,731000,-15743000,1763000,-4656000,8362000,-27240000,4553000,-769000,212604000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,15.290001,4.27095,3.58 - 20.4,-1.5299988,-0.07499994,3.58,20.4,1620331200,1635937140,1636372800,-0.782,0.2,0.71,-3.0318513,18.58 - 20.4,19.46,19.21,19.22,8,10,finmb_423490,NasdaqCM,Dynavax Technologies Corporation,USD,2951515,10139650,26.577467,0.533,11.395,7.4750004,0.65598947,9.807246,9.062755,0.9240876,2161804032,94.350006,35.403378,15,America/New_York,EDT,-14400000,2,NCM,REGULAR,us_market,Dynavax Technologies Corporatio,18.87,1630506458,-0.58999825,20.14,20.4,18.58,3588353,1.23,,,20.4,3.58,11.4,9.81,2.95M,10.14M,114.56M,,105.83M,0.31%,76.22%,20.28M,8.95,22.32%,17.67%,18.99M,,,,,,0.00%,,,1:10,"Nov 09, 2014","Dec 30, 2020","Jun 29, 2021",-3.37%,7.50%,1.62%,-8.05%,169.07M,1.51,"1,877.80%",6.53M,17.09M,-5.7M,-0.78,,345.8M,3.01,256.34M,307.44,2.85,0.53,105.26M,-1.16M,Value,94608,Healthcare,245,5,6,"Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.",EmeryVille,510 848 5100,CA,8,1609372800,1625097600,3,United States,http://www.dynavax.com,86400,5,2100 Powell Street,510 848 1327,Drug Manufacturers—Specialty & Generic,Suite 900
t-3,DVAX,67088000,114563000,,,4401000,,4401000,19612000,862000,-18750000,-18750000,,-4794000,,,,0,13414000,32164000,12552000,23151000,,4401000,4401000,1348793000,284111000,69284000,38072000,353395000,110000,-1278597000,2234000,2196000,-1022000,3464000,32688000,66625000,-1022000,57732000,290003000,144473000,35023000,179733000,59033000,5273000,-4648000,24272000,-2054000,29628000,1412000,-105000,1412000,-27788000,675000,-27821000,1748000,-4641000,-30120000,-27240000,-23376000,-265000,223378000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,15.290001,4.27095,3.58 - 20.4,-1.5299988,-0.07499994,3.58,20.4,1620331200,1635937140,1636372800,-0.782,0.2,0.71,-3.0318513,18.58 - 20.4,19.46,19.21,19.22,8,10,finmb_423490,NasdaqCM,Dynavax Technologies Corporation,USD,2951515,10139650,26.577467,0.533,11.395,7.4750004,0.65598947,9.807246,9.062755,0.9240876,2161804032,94.350006,35.403378,15,America/New_York,EDT,-14400000,2,NCM,REGULAR,us_market,Dynavax Technologies Corporatio,18.87,1630506458,-0.58999825,20.14,20.4,18.58,3588353,1.23,,,20.4,3.58,11.4,9.81,2.95M,10.14M,114.56M,,105.83M,0.31%,76.22%,20.28M,8.95,22.32%,17.67%,18.99M,,,,,,0.00%,,,1:10,"Nov 09, 2014","Dec 30, 2020","Jun 29, 2021",-3.37%,7.50%,1.62%,-8.05%,169.07M,1.51,"1,877.80%",6.53M,17.09M,-5.7M,-0.78,,345.8M,3.01,256.34M,307.44,2.85,0.53,105.26M,-1.16M,Value,94608,Healthcare,245,5,6,"Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.",EmeryVille,510 848 5100,CA,8,1609372800,1625097600,3,United States,http://www.dynavax.com,86400,5,2100 Powell Street,510 848 1327,Drug Manufacturers—Specialty & Generic,Suite 900
